Advertisement

Hormone und Skelettsystem (Übersichtsreferat)

  • R. Ziegler
Conference paper

Zusammenfassung

Hormone als chemische Boten steuern auch den Knochenstoffwechsel. Selbst wenn dieser in den kleinsten Arbeitseinheiten der Knochenumbaueinheit auch ohne „Hormonberieselung“autark ist, sind Reaktionen des Skelettes im sinnvollen Funktionieren des Gesamtorganismus nur mit Hülfe der Hormone möglich. Das Fehlen der Hormone führt zu unterschiedlichen Defektzuständen, die von der optimalen biologischen Leistung mehr oder weniger weit entfernt sind.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bressot C, Meunier PJ, Chapuy MC, LeJeune E, Edouard C, Darby AJ (1979) Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis. Metab Bone Dis Rel Res 1: 303–311CrossRefGoogle Scholar
  2. Civitelle R, Conelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C (1988) Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 82:1268–1274CrossRefGoogle Scholar
  3. Diamond T, Nery L. Hales I (1991) A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocr Metab 72:1184–1188PubMedCrossRefGoogle Scholar
  4. Etienne MC, Fischel JL, Milano G et al. (1990) Steroid receptors in human osteoblast-like cells. Eur J Cancer 26: 807–810PubMedCrossRefGoogle Scholar
  5. Fraser SA, Smith DA, Anderson JB, Wilson GM (1971) Osteoporosis and fractures following thyrotoxicosis. Lancet I: 981–983Google Scholar
  6. Frost HM (1983) The regional acceleratory phenomenon: a review. Henry Ford Hosp Med J 31: 3–9PubMedGoogle Scholar
  7. Frost MM (1983) Osteopenia: the ADFR treatment. In: Frame B, Potts jr JJ (eds) Clinical disorders of bone and mineral metabolism. Excerpta Medica, Amsterdam (ICS 617, pp 368–374)Google Scholar
  8. Hesch RD, Rittinghaus EF, Harms HM, Delling G (1989) Die Frühtherapie der Osteoporose mit (1–38) Parathormon und Calcitonin-Nasalspray. Med Klin 84: 488–498Google Scholar
  9. Hodsman AB, Steer BM, Fraher LJ, Drost DJ (1991) Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1–38) and salmon calcitonin in osteoporotic patients. Bone Miner 14: 67–83PubMedCrossRefGoogle Scholar
  10. Kruse K, Büsse M, Kracht U, Kruse U, Wohlfart K (1988) Kalzium- und Knochenstoffwechselstörungen unter Glukokortikoid-Behandlung. Monatsschr Kinderheilkd 136: 237–242PubMedGoogle Scholar
  11. Lempert UG, Minne HW, Fleisch H, Mühlbauer RC, Scharia SH, Ziegler R (1991) Inflammation-mediated osteopenia (IMO): No change in bone resorption during its development. Calcif Tissue Int 48: 291–292PubMedCrossRefGoogle Scholar
  12. Minne HW, Pfeilschifter J, Scharia S, Mutschelknauss S, Schwarz A, Krempien B, Ziegler R (1984) Inflammation-mediated osteopenia in the rat: A new animal model for pathological loss of bone mass. Endocrinology 115: 50–54PubMedCrossRefGoogle Scholar
  13. Müller M, Schilling T, Minne HW, Ziegler R (1991) A systemic acceleratory phenomenon (SAP) accompanies the regional acceleratory phenomenon (RAP) during healing of a bone defect in the rat. J Bone Miner Res 6: 401–410CrossRefGoogle Scholar
  14. Oursler MJ, Cortese C, Keeting P, Anderson MA, Bonde SK, Riggs BL, Spelsberg TC (1991) Modulation of transforming growth factor-β production in normal human osteoblast-like cells by 17β-estradiol and parathyroid hormone. Endocrinology 129: 3313–3320PubMedCrossRefGoogle Scholar
  15. Paul TL, Kerrigan J, Kelly AM, Braverman LE, Baran DT (1988) Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women. JAMA 259: 3137–3141PubMedCrossRefGoogle Scholar
  16. Ribot C, Trémollières F, Pouilles JM, Louvet JP (1990) Bone mineral density and thyroid hormone therapy. Clin Endocrinol 33:143–153CrossRefGoogle Scholar
  17. Stall GM, Harris S, Sokoli LJ, Dawson-Hughes B (1990) Accelerated bone loss in hypothyroid patients over-treated with L-thyroxine. Ann Intern Med 113: 265–269PubMedGoogle Scholar
  18. Steiniche T, Hasling C, Charles P, Eriksen EF, Meisen F, Mosekilde L (1991) The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: a randomized study comparing intermittent treatment and an ADFR regime. Bone 12:155–163PubMedCrossRefGoogle Scholar
  19. Tilyard MW, Spears GFS, Thomson J, Dovey S (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326: 357–362PubMedCrossRefGoogle Scholar
  20. Toh SH, Brown PH (1990) Bone mineral content in hypothyroid male patients with hormone replacement: a 3-year study. J Bone Min Res 51: 463–467CrossRefGoogle Scholar
  21. Tsai K-S, Heath III H, Kumar R, Riggs BL (1984) Impaired vitamin D metabolism with aging in women. Possible role in pathogenesis of senile osteoporosis. J Clin Invest 73:1668–1672PubMedCrossRefGoogle Scholar
  22. Watts NB, Harris ST, Genant HK et al. (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323: 73–79PubMedCrossRefGoogle Scholar
  23. Wüster C, Slenczka E, Ziegler R (1991) Erhöhte Prävalenz von Osteoporose und Arteriosklerose bei konventionell substituierter Hypophysenvorderlappeninsuffizienz: Bedarf einer zusätzlichen Wachstumshormonsubstitution? Klin Wochenschr 69: 769–773PubMedCrossRefGoogle Scholar
  24. Wüster C, Raue F, Meyer C, Bockmühl M, Ugurel A, Bergmann M, Ziegler R (1992a) Long-term excess of endogenous calcitonin in patients with medullary thyroid carcinoma does not affect bone mineral density. J Endocrinol 134Google Scholar
  25. Wüster C, Blum WF, Schlemilch S, Ranke MB, Ziegler R (1992b) Decreased serum levels of insulin like growth factors 1 and 2 and IGF binding protein-3 in patients with osteoporosis. Growth, development and aging. Zur Publikation angenommen (1992)Google Scholar
  26. Ziegler R (1985) Die physiologische Rolle des Calcitonins. Therapiewoche 35: 972–982Google Scholar
  27. Ziegler R (1992) Bedeutung von „Risikofaktoren“ der Osteoporose als Indikationshilfe für die Östrogen-Gestagen-Prävention. Med Welt 43:169–172Google Scholar
  28. Ziegler R, Minne H, Raue F, Paar G, Delling G (1975) Beobachtungen zur Vitamin-D- und Dihydrotachysterin-Vergiftung. Dtsch Med Wochenschr 100: 415–423PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • R. Ziegler
    • 1
  1. 1.Abteilung Innere Medizin I (Endokrinologie und Stoffwechsel)Medizinische UniversitätsklinikHeidelbergDeutschland

Personalised recommendations